Related Experiment Video

Updated: Dec 9, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.4K

Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

Laura Esteban-Burgos1, Haiyun Wang2, Patricia Nieto1

  • 1Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas, 28029 Madrid, Spain.

Proceedings of the National Academy of Sciences of the United States of America
|September 11, 2020
PubMed

Insights

Targeting CDK4 and RAF1 shows promise for KRAS mutant lung cancer. Combination therapy can induce regression, and resistant cells can be pharmacologically controlled, offering new treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • KRAS-mutant lung adenocarcinomas are difficult to treat with current targeted therapies.
  • Identifying effective therapeutic targets within KRAS downstream pathways is crucial for developing new treatments.

Purpose of the Study:

  • To identify genetic targets for KRAS-mutant lung cancer therapy.
  • To investigate resistance mechanisms to CDK4 and RAF1 inactivation.
  • To explore pharmacological control of resistant KRAS-mutant lung cancer cells.

Main Methods:

  • Genetic interrogation of KRAS downstream effectors, including MAPK pathway and interphase CDKs.
  • Inactivation of CDK4 and RAF1 in KRAS/p53-driven lung tumors.
  • Characterization of resistant cell populations using molecular analyses.
  • Pharmacological studies on resistant cells.

Main Results:

  • CDK4 and RAF1 were identified as key targets for genetic inactivation, yielding therapeutic responses.
  • Concomitant CDK4 inactivation and RAF1 ablation led to tumor regression in a subset of KRAS/p53-driven lung tumors.
  • Resistance mechanisms involved tumor suppressor hypermethylation and increased PI3K activity.
  • CDK4/RAF1-resistant cells demonstrated susceptibility to pharmacological intervention.

Conclusions:

  • Targeting CDK4 and RAF1 represents a viable therapeutic strategy for KRAS-mutant lung cancer.
  • Understanding and addressing resistance mechanisms, such as hypermethylation and PI3K activation, is essential for durable responses.
  • Pharmacological strategies can overcome resistance, paving the way for combination therapies against KRAS-mutant lung cancer.
Keywords:
CDK4/RAF1 inhibitionKRASLung CancerResistance MechanismsTumor Regression

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.4K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K